Symptom aggravation after withdrawal of metal chelating agent therapy in patients with Wilson's disease

被引:2
|
作者
Zhou, Xiangxue [1 ]
Liao, Jian [1 ]
Liu, Yinjie [1 ]
Qin, Haolin [2 ]
Xiao, Xia [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol, Guangdong Prov Key Lab Diag & Treatment Major Neur, 58 Zhongshan Rd, Guangzhou 510080, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Imaging, Guangzhou, Peoples R China
来源
BRAIN AND BEHAVIOR | 2023年 / 13卷 / 09期
关键词
disease stage; drug discontinuance; metal chelating agent; symptoms aggravated; Wilson disease;
D O I
10.1002/brb3.3170
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
ObjectiveTo study the aggravation of clinical symptoms after discontinuation of metal chelating agent therapy in Wilson's disease (WD) patients, analyze the causes of aggravation, and observe the prognosis. Methods40 WD patients (cerebral type 30 cases and hepatic type 10 cases) who stopped using metal chelating agent were selected, 40 WD patients with normal therapy, and 10 normal control cases were selected. All patients underwent neurological symptom evaluation using modified Young scale, Child-Pugh liver function grading, metal metabolism, and disease typing. Magnetic sensitivity imaging (SWI), diffusion tensor imaging (DTI), and magnetic resonance spectroscopy imaging (MRS) were performed. According to the imaging results, WD patients were divided into metal deposition stage, fiber damage stage, and neuron necrosis stage. All patients were treated with metal chelating agent for 6 months. ResultsThe score of modified Young scale in drug withdrawal group was lower than that in normal treatment group before drug withdrawal (p = .032). The score of modified Young scale was higher after drug withdrawal than before (p = .011). The number of Child-Pugh B-grade patients after drug withdrawal was more than that before drug withdrawal and in normal treatment group. The proportion of patients in the stage of neuronal necrosis after drug withdrawal (25%) was higher than that before drug withdrawal (10%) (p = .025). After drug withdrawal, urine copper was significantly higher than that before drug withdrawal and in the normal treatment group (p = .032, .039). After the withdrawal group resumed metal chelating agent treatment, 34.2% of neurological symptoms worsened. ConclusionsWD patients showed neurological symptoms aggravation and increased liver injury after metal chelating agent withdrawal. Increased metal deposition and new nerve injury occurred in the brain. After re-treatment, the aggravated neurological symptoms of WD patients are difficult to reverse.
引用
收藏
页数:8
相关论文
共 37 条
  • [1] Hyaluronate/black phosphorus complexes as a copper chelating agent for Wilson disease treatment
    Seong-Jong Kim
    Hye Hyeon Han
    Sei Kwang Hahn
    Biomaterials Research, 25
  • [2] Hyaluronate/black phosphorus complexes as a copper chelating agent for Wilson disease treatment
    Kim, Seong-Jong
    Han, Hye Hyeon
    Hahn, Sei Kwang
    BIOMATERIALS RESEARCH, 2021, 25 (01)
  • [3] Role of Oxidative Stress in the Worsening of Neurologic Wilson Disease Following Chelating Therapy
    Jayantee Kalita
    Vijay Kumar
    Abhay Ranjan
    Usha K. Misra
    NeuroMolecular Medicine, 2015, 17 : 364 - 372
  • [4] Role of Oxidative Stress in the Worsening of Neurologic Wilson Disease Following Chelating Therapy
    Kalita, Jayantee
    Kumar, Vijay
    Ranjan, Abhay
    Misra, Usha K.
    NEUROMOLECULAR MEDICINE, 2015, 17 (04) : 364 - 372
  • [5] Excess Copper Chelating Therapy for Wilson Disease Induces Anemia and Liver Dysfunction
    Harada, Masaru
    Miyagawa, Koichiro
    Honma, Yuichi
    Hiura, Masaaki
    Shibata, Michihiko
    Matsuhashi, Toru
    Abe, Shintaro
    Harada, Riko
    Tabaru, Akinari
    INTERNAL MEDICINE, 2011, 50 (14) : 1461 - 1464
  • [6] Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: Promising, safe and cheap
    Sinha, S.
    Taly, A. B.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2008, 264 (1-2) : 129 - 132
  • [7] EAEP and morphometry of mesencephal region in patients with Wilson's disease
    Hermann, W.
    Guenther, P.
    Kuehn, H. J.
    Schneider, J. P.
    Eichelkraut, S.
    Villmann, T.
    Strecker, K.
    Schwarz, J.
    Wagner, A.
    AKTUELLE NEUROLOGIE, 2007, 34 (10) : 547 - 554
  • [8] Neuropsychiatric disturbances in Wilson's disease and use of electroconvulsive therapy: case report
    Rodrigues, ACT
    Dalgalarrondo, P
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2003, 61 (3B) : 876 - 880
  • [9] Effect of chelation therapy in pediatric Wilson's disease: Liver and endoscopic outcome
    Das, Mridul Chandra
    Sen Sarma, Moinak
    Srivastava, Anshu
    Yachha, Surender Kumar
    Poddar, Ujjal
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2021, 28 (04) : 336 - 345
  • [10] Quality of Life in Patients with Treated and Clinically Stable Wilson's Disease
    Svetel, Marina
    Pekmezovic, Tatjana
    Tomic, Aleksandra
    Kresojevic, Nikola
    Potrebic, Aleksandra
    Jesic, Rada
    Kostic, Vladimir S.
    MOVEMENT DISORDERS, 2011, 26 (08) : 1503 - 1508